Compare Stocks

Date Range: 

 Constellation PharmaceuticalsKiniksa PharmaceuticalsOmerosZogenixPliant Therapeutics
SymbolNASDAQ:CNSTNASDAQ:KNSANASDAQ:OMERNASDAQ:ZGNXNASDAQ:PLRX
Price Information
Current Price$20.80$14.63$17.75$18.87$32.90
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.21.71.41.72.0
Analysis Score3.43.53.33.43.5
Community Score2.42.43.02.84.6
Dividend Score0.00.00.00.00.0
Ownership Score0.02.50.81.71.7
Earnings & Valuation Score0.00.00.00.60.0
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$40.33$37.00$23.00$59.00$49.20
% Upside from Price Target93.91% upside152.90% upside29.58% upside212.67% upside49.54% upside
Trade Information
Market Cap$996.61 million$998.23 million$1.11 billion$1.05 billion$1.18 billion
Beta2.80.031.651.6N/A
Average Volume462,367478,515697,663797,062156,618
Sales & Book Value
Annual RevenueN/AN/A$111.81 million$3.65 million$57.05 million
Price / SalesN/AN/A9.89288.5520.69
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$8.23 per share$4.10 per share($2.19) per share$5.54 per shareN/A
Price / BookN/AN/A-8.113.41
Profitability
Net Income$-85,550,000.00$-161,870,000.00$-84,490,000.00$-419,500,000.00$-630,000.00
EPS($3.04)($2.99)($0.96)($3.90)N/A
Trailing P/E RatioN/AN/AN/AN/A0.00
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/A-134.59%-8,758.48%20.83%
Return on Equity (ROE)-28.88%-53.65%N/A-53.91%16.55%
Return on Assets (ROA)-24.98%-49.11%-59.49%-36.49%8.33%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.05%N/AN/AN/AN/A
Current Ratio15.81%15.20%4.11%4.58%27.91%
Quick Ratio15.81%15.20%4.07%4.58%27.91%
Ownership Information
Institutional Ownership PercentageN/A42.00%56.63%96.57%79.46%
Insider Ownership Percentage10.60%70.63%11.30%3.50%N/A
Miscellaneous
Employees15416827721878
Shares Outstanding47.91 million68.23 million62.33 million55.81 million35.88 million
Next Earnings Date5/10/2021 (Confirmed)7/29/2021 (Estimated)5/10/2021 (Confirmed)8/4/2021 (Estimated)6/15/2021 (Estimated)
OptionableNot OptionableNot OptionableOptionableOptionableNot Optionable
SourceHeadline
Pliant Therapeutics (NASDAQ:PLRX) Sees Unusually-High Trading VolumePliant Therapeutics (NASDAQ:PLRX) Sees Unusually-High Trading Volume
americanbankingnews.com - May 7 at 11:54 AM
Analyzing Pliant Therapeutics (NASDAQ:PLRX) and Astellas Pharma (OTCMKTS:ALPMY)Analyzing Pliant Therapeutics (NASDAQ:PLRX) and Astellas Pharma (OTCMKTS:ALPMY)
americanbankingnews.com - May 6 at 1:48 PM
Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare ConferencePliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference
finance.yahoo.com - May 5 at 12:13 PM
Pliant Therapeutics (NASDAQ:PLRX) Shares Gap Down to $33.50Pliant Therapeutics (NASDAQ:PLRX) Shares Gap Down to $33.50
americanbankingnews.com - May 3 at 12:04 PM
We Think Pliant Therapeutics (NASDAQ:PLRX) Can Afford To Drive Business GrowthWe Think Pliant Therapeutics (NASDAQ:PLRX) Can Afford To Drive Business Growth
nasdaq.com - May 1 at 2:29 PM
Pliant Therapeutics Inc (PLRX)Pliant Therapeutics Inc (PLRX)
investing.com - April 30 at 1:54 PM
Pliant Therapeutics (NASDAQ:PLRX) Trading Down 5.2%Pliant Therapeutics (NASDAQ:PLRX) Trading Down 5.2%
americanbankingnews.com - April 28 at 12:38 PM
Pliant Therapeutics (NASDAQ:PLRX) Earns Buy Rating from Analysts at BTIG ResearchPliant Therapeutics (NASDAQ:PLRX) Earns Buy Rating from Analysts at BTIG Research
americanbankingnews.com - April 26 at 11:00 AM
Pliant Therapeutics (NASDAQ:PLRX) Now Covered by BTIG ResearchPliant Therapeutics (NASDAQ:PLRX) Now Covered by BTIG Research
marketbeat.com - April 26 at 8:59 AM
Pliant Therapeutics (NASDAQ:PLRX) PT Raised to $63.00Pliant Therapeutics (NASDAQ:PLRX) PT Raised to $63.00
americanbankingnews.com - April 22 at 11:08 AM
Pliant Therapeutics (NASDAQ:PLRX) Shares Up 5.6% After Analyst UpgradePliant Therapeutics (NASDAQ:PLRX) Shares Up 5.6% After Analyst Upgrade
americanbankingnews.com - April 22 at 10:24 AM
Pliant Therapeutics (NASDAQ:PLRX) Shares Gap Up to $28.42Pliant Therapeutics (NASDAQ:PLRX) Shares Gap Up to $28.42
americanbankingnews.com - April 20 at 12:00 PM
BTIG Research Initiates Coverage on Pliant Therapeutics (NASDAQ:PLRX)BTIG Research Initiates Coverage on Pliant Therapeutics (NASDAQ:PLRX)
americanbankingnews.com - April 20 at 10:52 AM
Pliant Therapeutics (NASDAQ:PLRX) Shares Gap Down to $30.64Pliant Therapeutics (NASDAQ:PLRX) Shares Gap Down to $30.64
americanbankingnews.com - April 19 at 12:02 PM
Pliant Therapeutics, Inc. (NASDAQ:PLRX) CEO Bernard Coulie Sells 3,500 SharesPliant Therapeutics, Inc. (NASDAQ:PLRX) CEO Bernard Coulie Sells 3,500 Shares
americanbankingnews.com - April 15 at 10:34 PM
Pliant Therapeutics (NASDAQ:PLRX) Sees Strong Trading VolumePliant Therapeutics (NASDAQ:PLRX) Sees Strong Trading Volume
americanbankingnews.com - April 15 at 11:40 AM
Analyzing The Price Action In Pliant Therapeutics Stock TodayAnalyzing The Price Action In Pliant Therapeutics Stock Today
msn.com - April 5 at 12:00 PM
Pliant Therapeutics to Participate in Annual Needham Virtual Healthcare ConferencePliant Therapeutics to Participate in Annual Needham Virtual Healthcare Conference
finance.yahoo.com - April 5 at 12:00 PM
Were Not Very Worried About Pliant Therapeutics (NASDAQ:PLRX) Cash Burn RateWe're Not Very Worried About Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Rate
finance.yahoo.com - March 22 at 2:32 PM
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 ...Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 ...
apnews.com - March 16 at 7:33 PM
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial ResultsPliant Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results
finance.yahoo.com - March 16 at 7:33 PM
Pliant Therapeutics Announces Successful Completion of PLN-1474 Phase 1 Study and Development Transition to Global Pharmaceutical PartnerPliant Therapeutics Announces Successful Completion of PLN-1474 Phase 1 Study and Development Transition to Global Pharmaceutical Partner
finance.yahoo.com - March 16 at 9:30 AM
Pliant Therapeutics Announces Successful Completion of PLN-1474 Phase 1 Study  and Development Transition to Global Pharmaceutical PartnerPliant Therapeutics Announces Successful Completion of PLN-1474 Phase 1 Study and Development Transition to Global Pharmaceutical Partner
finance.yahoo.com - March 16 at 9:30 AM
Pliant Therapeutics to Participate in Upcoming Virtual Investor EventsPliant Therapeutics to Participate in Upcoming Virtual Investor Events
finance.yahoo.com - February 18 at 1:01 PM
Creating More Affordable Homes for Families in Red LakeCreating More Affordable Homes for Families in Red Lake
finance.yahoo.com - February 17 at 9:45 AM
Why a small Peninsula biotech thinks it can make a quick difference against CovidWhy a small Peninsula biotech thinks it can make a quick difference against Covid
bizjournals.com - January 14 at 5:58 PM
DateCompanyBrokerageAction
4/7/2021Constellation PharmaceuticalsRoyal Bank of CanadaReiterated Rating
1/25/2021Constellation PharmaceuticalsBMO Capital MarketsUpgrade
9/24/2020Constellation PharmaceuticalsOppenheimerReiterated Rating
9/3/2020Constellation PharmaceuticalsBrookline Capital ManagementInitiated Coverage
8/9/2020Constellation PharmaceuticalsJefferies Financial GroupReiterated Rating
8/6/2020Constellation PharmaceuticalsHC WainwrightReiterated Rating
6/24/2020Constellation PharmaceuticalsJMP SecuritiesInitiated Coverage
3/11/2020Constellation PharmaceuticalsRobert W. BairdLower Price Target
3/11/2020Constellation PharmaceuticalsCowenReiterated Rating
2/13/2020Constellation PharmaceuticalsSunTrust BanksInitiated Coverage
11/24/2020Kiniksa PharmaceuticalsEvercore ISIInitiated Coverage
6/30/2020Kiniksa PharmaceuticalsThe Goldman Sachs GroupBoost Price Target
6/29/2020Kiniksa PharmaceuticalsBank of AmericaBoost Price Target
6/29/2020Kiniksa PharmaceuticalsWedbushBoost Price Target
3/11/2020Kiniksa PharmaceuticalsJPMorgan Chase & Co.Boost Price Target
3/11/2019Kiniksa PharmaceuticalsBarclaysInitiated Coverage
2/1/2021OmerosUBS GroupInitiated Coverage
12/4/2020OmerosMaxim GroupBoost Price Target
5/12/2020OmerosNeedham & Company LLCReiterated Rating
12/2/2020ZogenixMizuhoReiterated Rating
8/24/2020ZogenixRaymond JamesInitiated Coverage
8/6/2020ZogenixNorthland SecuritiesReiterated Rating
6/26/2020ZogenixWilliam BlairReiterated Rating
5/5/2020ZogenixPiper SandlerLower Price Target
3/5/2020ZogenixCitigroupInitiated Coverage
2/28/2020ZogenixLADENBURG THALM/SH SHReiterated Rating
2/14/2020ZogenixStifel NicolausReiterated Rating
1/21/2020ZogenixGuggenheimReiterated Rating
12/6/2019ZogenixPiper Jaffray CompaniesReiterated Rating
4/26/2021Pliant TherapeuticsBTIG ResearchInitiated Coverage
4/5/2021Pliant TherapeuticsCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellInitiated Coverage
(Data available from 5/9/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.